Properties (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
leuprolide
|
| gptkbp:availability |
prescription only
|
| gptkbp:chemicalFormula |
gonadotropin-releasing hormone agonist
|
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:commonName |
11.25 mg every three months
22.5 mg every six months 3.75 mg monthly |
| gptkbp:community_service |
available
|
| gptkbp:contraindication |
cardiovascular issues
gastrointestinal disturbances pregnancy breastfeeding injection site reactions osteoporosis hypersensitivity to leuprolide |
| gptkbp:date |
FDA_approved
|
| gptkbp:dosageForm |
injectable solution
|
| gptkbp:drugInterdiction |
anticoagulants
hormonal therapies antidiabetic medications |
| gptkbp:firstAppearance |
1985
|
| gptkbp:formulation |
monthly injection
depot injection three-month injection |
| gptkbp:hasPopulation |
children
women adult men |
| https://www.w3.org/2000/01/rdf-schema#label |
Lupron-PED
|
| gptkbp:impact |
varies by condition
|
| gptkbp:is_monitored_by |
bone density
symptom relief hormone levels |
| gptkbp:manufacturer |
AbbVie
|
| gptkbp:marketedAs |
gptkb:Lupron
gptkb:Lupron_Depot gptkb:Lupron-PED |
| gptkbp:offers |
varies by insurance
can be expensive without insurance |
| gptkbp:patentStatus |
patented
|
| gptkbp:route |
intramuscular injection
subcutaneous injection |
| gptkbp:sideEffect |
fatigue
nausea weight gain mood changes hot flashes |
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
suppresses gonadotropin secretion
|
| gptkbp:type |
leuprolide acetate
|
| gptkbp:usedFor |
treatment of prostate cancer
treatment of precocious puberty treatment of endometriosis |